Clinical relevance of cytomegalovirus infection in patients with disorders of the immune system

Clinical Microbiology and Infection

Volumn 13, Issue 10, 2007, Pages 953-963

  Steininger, Christoph ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Clinical complications; Cytomegalovirus; Guillain Barr syndrome; Immunocompromised patients; Review; Transplant recipients

Indexed keywords

ANTIRETROVIRUS AGENT; CYTOMEGALOVIRUS ANTIBODY; GANCICLOVIR; VIRUS ANTIGEN;

CD4 LYMPHOCYTE COUNT; CLINICAL FEATURE; CLINICAL TRIAL; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DISEASE ACTIVITY; EYE CHAMBER DISEASE; GENETIC VARIABILITY; GENOTYPE; GRAFT INFECTION; GRAFT REJECTION; GUILLAIN BARRE SYNDROME; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOCOMPROMISED PATIENT; IMMUNOPATHOLOGY; INFECTION PREVENTION; INFECTION RISK; NONHUMAN; PATHOGENESIS; PATIENT ATTITUDE; PRIORITY JOURNAL; RETINITIS; REVIEW; RISK FACTOR; TREATMENT DURATION; VIRUS ACTIVATION; VIRUS IMMUNITY; VIRUS TRANSMISSION;

CYTOMEGALOVIRUS; HUMAN IMMUNODEFICIENCY VIRUS;

EID: 34548540475     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2007.01781.x     Document Type: Review

References (120)

1. Mocarski ES. Cytomegaloviruses and their replication, 3rd edn. Philadelphia: Lippincott-Raven, 1996; 2447-2492.
2. Munro SC, Hall B, Whybin LR et al. Diagnosis of and screening for cytomegalovirus infection in pregnant women. J Clin Microbiol 2005; 43: 4713-4718.
3. Collier AC, Meyers JD, Corey L, Murphy VL, Roberts PL, Handsfield HH. Cytomegalovirus infection in homosexual men. Relationship to sexual practices, antibody to human immunodeficiency virus, and cell-mediated immunity. Am J Med 1987; 82: 593-601.
4. Guinan ME, Thomas PA, Pinsky PF et al. Heterosexual and homosexual patients with the acquired immunodeficiency syndrome. A comparison of surveillance, interview, and laboratory data. Ann Intern Med 1984; 100: 213-218.
5. Ling PD, Lednicky JA, Keitel WA et al. The dynamics of herpesvirus and polyomavirus reactivation and shedding in healthy adults: A 14-month longitudinal study. J Infect Dis 2003; 187: 1571-1580.
6. Mehta SK, Stowe RP, Feiveson AH, Tyring SK, Pierson DL. Reactivation and shedding of cytomegalovirus in astronauts during spaceflight. J Infect Dis 2000; 182: 1761-1764.
7. Sia IG, Patel R. New strategies for prevention and therapy of cytomegalovirus infection and disease in solid-organ transplant recipients. Clin Microbiol Rev 2000; 13: 83-121.
8. Yust I, Fox Z, Burke M et al. Retinal and extraocular cytomegalovirus end-organ disease in HIV-infected patients in Europe: A EuroSIDA study, 1994-2001. Eur J Clin Microbiol Infect Dis 2004; 23: 550-559.
9. Dummer JS, Hardy A, Poorsattar A, Ho M. Early infections in kidney, heart, and liver transplant recipients on cyclosporine. Transplantation 1983; 36: 259-267.
10. Rubin RH, Kemmerly SA, Conti D et al. Prevention of primary cytomegalovirus disease in organ transplant recipients with oral ganciclovir or oral acyclovir prophylaxis. Transpl Infect Dis 2000; 2: 112-117.
11. Hartmann A, Sagedal S, Hjelmesaeth J. The natural course of cytomegalovirus infection and disease in renal transplant recipients. Transplantation 2006; 82: S15-S17.
12. Gallant JE, Moore RD, Richman DD, Keruly J, Chaisson RE. Incidence and natural history of cytomegalovirus disease in patients with advanced human immunodeficiency virus disease treated with zidovudine. The Zidovudine Epidemiology Study Group. J Infect Dis 1992; 166: 1223-1227.
13. Cinque P, Cleator GM, Weber T et al. Diagnosis and clinical management of neurological disorders caused by cytomegalovirus in AIDS patients. European Union Concerted Action on Virus Meningitis and Encephalitis. J Neurovirol 1998; 4: 120-132.
14. Kanj SS, Sharara AI, Clavien PA, Hamilton JD. Cytomegalovirus infection following liver transplantation: Review of the literature. Clin Infect Dis 1996; 22: 537-549.
15. Ho M. Advances in understanding cytomegalovirus infection after transplantation. Transplant Proc 1994; 26: 7-11.
16. Patel R, Paya CV. Infections in solid-organ transplant recipients. Clin Microbiol Rev 1997; 10: 86-124.
17. Kestelyn PG, Cunningham ET. HIV/AIDS and blindness. Bull WHO 2001; 79: 208-213.
18. Nguyen QD, Kempen JH, Bolton SG, Dunn JP, Jabs DA. Immune recovery uveitis in patients with AIDS and cytomegalovirus retinitis after highly active antiretroviral therapy. Am J Ophthalmol 2000; 129: 634-639.
19. Karavellas MP, Lowder CY, Macdonald C, Avila CP, Freeman WR. Immune recovery vitritis associated with inactive cytomegalovirus retinitis: A new syndrome. Arch Ophthalmol 1998; 116: 169-175.
20. Zegans ME, Walton RC, Holland GN, O'Donnell JJ, Jacobson MA, Margolis TP. Transient vitreous inflammatory reactions associated with combination antiretroviral therapy in patients with AIDS and cytomegalovirus retinitis. Am J Ophthalmol 1998; 125: 292-300.
21. Hengel H, Brune W, Koszinowski UH. Immune evasion by cytomegalovirus - survival strategies of a highly adapted opportunist. Trends Microbiol 1998; 6: 190-197.
22. Waiser J, Budde K, Schreiber M et al. Effectiveness of deferred therapy with ganciclovir in renal allograft recipients with cytomegalovirus disease. Transplant Proc 1998; 30: 2083-2085.
23. Duncan SR, Grgurich WF, Iacono AT et al. A comparison of ganciclovir and acyclovir to prevent cytomegalovirus after lung transplantation. Am J Respir Crit Care Med 1994; 150: 146-152.
24. Roberts TC, Brennan DC, Buller RS et al. Quantitative polymerase chain reaction to predict occurrence of symptomatic cytomegalovirus infection and assess response to ganciclovir therapy in renal transplant recipients. J Infect Dis 1998; 178: 626-635.
25. Lebranchu Y, al Najjar A, Kapahi P et al. The association of increased soluble VCAM-1 levels with CMV disease in human kidney allograft recipients. Transplant Proc 1995; 27: 960.
26. Kas-Deelen AM, Harmsen MC, de Maar EF et al. Acute rejection before cytomegalovirus infection enhances von Willebrand factor and soluble VCAM-1 in blood. Kidney Int 2000; 58: 2533-2542.
27. Lowance D, Neumayer HH, Legendre CM et al. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group. N Engl J Med 1999; 340: 1462-1470.
28. Hjelmesaeth J, Sagedal S, Hartmann A et al. Asymptomatic cytomegalovirus infection is associated with increased risk of new-onset diabetes mellitus and impaired insulin release after renal transplantation. Diabetologia 2004; 47: 1550-1556.
29. George MJ, Snydman DR, Werner BG et al. The independent role of cytomegalovirus as a risk factor for invasive fungal disease in orthotopic liver transplant recipients. Boston Center for Liver Transplantation CMVIG-Study Group. Cytogam, MedImmune, Inc. Gaithersburg, Maryland. Am J Med 1997; 103: 106-113.
30. Lemstrom K, Koskinen P, Krogerus L, Daemen M, Bruggeman C, Hayry P. Cytomegalovirus antigen expression, endothelial cell proliferation, and intimal thickening in rat cardiac allografts after cytomegalovirus infection. Circulation 1995; 92: 2594-2604.
31. Webster A, Lee CA, Cook DG et al. Cytomegalovirus infection and progression towards AIDS in haemophiliacs with human immunodeficiency virus infection. Lancet 1989; ii: 63-66.
32. Sabin CA, Devereux HL, Clewley G et al. Cytomegalovirus seropositivity and human immunodeficiency virus type 1 RNA levels in individuals with hemophilia. J Infect Dis 2000; 181: 1800-1803.
33. Sabin CA, Phillips AN, Lee CA, Janossy G, Emery V, Griffiths PD. The effect of CMV infection on progression of human immunodeficiency virus disease is a cohort of haemophilic men followed for up to 13 years from seroconversion. Epidemiol Infect 1995; 114: 361-372.
34. Robain M, Boufassa F, Hubert JB, Persoz A, Burgard M, Meyer L. Cytomegalovirus seroconversion as a cofactor for progression to AIDS. AIDS 2001; 15: 251-256.
35. Snydman DR. Counterpoint: Prevention of cytomegalovirus (CMV) infection and CMV disease in recipients of solid organ transplants: The case for prophylaxis. Clin Infect Dis 2005; 40: 709-712.
36. Munoz-Price LS, Slifkin M, Ruthazer R et al. The clinical impact of ganciclovir prophylaxis on the occurrence of bacteremia in orthotopic liver transplant recipients. Clin Infect Dis 2004; 39: 1293-1299.
37. Valantine HA, Gao SZ, Menon SG et al. Impact of prophylactic immediate posttransplant ganciclovir on development of transplant atherosclerosis: a post hoc analysis of a randomized, placebo-controlled study. Circulation 1999; 100: 61-66.
38. Gane E, Saliba F, Valdecasas GJ et al. Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients. The Oral Ganciclovir International Transplantation Study Group. Lancet 1997; 350: 1729-1733.
39. Kalil AC, Levitsky J, Lyden E, Stoner J, Freifeld AG. Meta-analysis: The efficacy of strategies to prevent organ disease by cytomegalovirus in solid organ transplant recipients. Ann Intern Med 2005; 143: 870-880.
40. Bowen EF, Griffiths PD, Davey CC, Emery VC, Johnson MA. Lessons from the natural history of cytomegalovirus. AIDS 1996; 10 (suppl 1): S37-S41.
41. Jabs DA, Enger C, Bartlett JG. Cytomegalovirus retinitis and acquired immunodeficiency syndrome. Arch Ophthalmol 1989; 107: 75-80.
42. Pertel P, Hirschtick R, Phair J, Chmiel J, Poggensee L, Murphy R. Risk of developing cytomegalovirus retinitis in persons infected with the human immunodeficiency virus. J AIDS 1992; 5: 1069-1074.
43. Drew WL. Cytomegalovirus infection in patients with AIDS. Clin Infect Dis 1992; 14: 608-615.
44. Hoover DR, Saah AJ, Bacellar H et al. Clinical manifestations of AIDS in the era of pneumocystis prophylaxis. Multicenter AIDS Cohort Study. N Engl J Med 1993; 329: 1922-1926.
45. Palella FJ, Delaney KM, Moorman AC et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338: 853-860.
46. O'Sullivan CE, Drew WL, McMullen DJ et al. Decrease of cytomegalovirus replication in human immunodeficiency virus infected-patients after treatment with highly active antiretroviral therapy. J Infect Dis 1999; 180: 847-849.
47. Deayton JR. Changing trends in cytomegalovirus disease in HIV-infected patients. Herpes 2001; 8: 37-40.
48. Detels R, Tarwater P, Phair JP, Margolick J, Riddler SA, Munoz A. Effectiveness of potent antiretroviral therapies on the incidence of opportunistic infections before and after AIDS diagnosis. AIDS 2001; 15: 347-355.
49. Ledergerber B, Egger M, Erard V et al. AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy: the Swiss HIV Cohort Study. JAMA 1999; 282: 2220-2226.
50. Mocroft A, Katlama C, Johnson AM et al. AIDS across Europe, 1994-98: The EuroSIDA study. Lancet 2000; 356: 291-296.
51. Steininger C. Novel therapies for cytomegalovirus disease. Recent Patents Anti-Infective Drug Discovery 2007; 2: 53-72.
52. Lurain NS, Thompson KD, Holmes EW, Read GS. Point mutations in the DNA polymerase gene of human cytomegalovirus that result in resistance to antiviral agents. J Virol 1992; 66: 7146-7152.
53. Sullivan V, Talarico CL, Stanat SC, Davis M, Coen DM, Biron KK. A protein kinase homologue controls phosphorylation of ganciclovir in human cytomegalovirus-infected cells. Nature 1992; 359: 85.
54. Lurain NS, Spafford LE, Thompson KD. Mutation in the UL97 open reading frame of human cytomegalovirus strains resistant to ganciclovir. J Virol 1994; 68: 4427-4431.
55. Sullivan V, Biron KK, Talarico C et al. A point mutation in the human cytomegalovirus DNA polymerase gene confers resistance to ganciclovir and phosphonylmethoxyalkyl derivatives. Antimicrob Agents Chemother 1993; 37: 19-25.
56. Jabs DA, Dunn JP, Enger C, Forman M, Bressler N, Charache P. Cytomegalovirus retinitis and viral resistance. Prevalence of resistance at diagnosis, 1994. Cytomegalovirus Retinitis and Viral Resistance Study Group. Arch Ophthalmol 1996; 114: 809-814.
57. Bienvenu B, Thervet E, Bedrossian J et al. Development of cytomegalovirus resistance to ganciclovir after oral maintenance treatment in a renal transplant recipient. Transplantation 2000; 69: 182-184.
58. Limaye AP, Corey L, Koelle DM, Davis CL, Boeckh M. Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants. Lancet 2000; 356: 645-649.
59. Little SJ, Holte S, Routy JP et al. Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med 2002; 347: 385-394.
60. Salmon-Ceron D, Mazeron MC, Chaput S et al. Plasma cytomegalovirus DNA, pp65 antigenaemia and a low CD4 cell count remain risk factors for cytomegalovirus disease in patients receiving highly active antiretroviral therapy. AIDS 2000; 14: 1041-1049.
61. Mitchell SM, Membrey WL, Youle MS, Obi A, Worrell S, Gazzard BG. Cytomegalovirus retinitis after the initiation of highly active antiretroviral therapy: A 2 year prospective study. Br J Ophthalmol 1999; 83: 652-655.
62. Jacobson MA, Stanley H, Holtzer C, Margolis TP, Cunningham ET. Natural history and outcome of new AIDS-related cytomegalovirus retinitis diagnosed in the era of highly active antiretroviral therapy. Clin Infect Dis 2000; 30: 231-233.
63. Kaufmann GR, Perrin L, Pantaleo G et al. CD4 T-lymphocyte recovery in individuals with advanced HIV-1 infection receiving potent antiretroviral therapy for 4 years: The Swiss HIV Cohort Study. Arch Intern Med 2003; 163: 2187-2195.
64. Wolff AJ, O'Donnell AE. Pulmonary manifestations of HIV infection in the era of highly active antiretroviral therapy. Chest 2001; 120: 1888-1893.
65. Huang ES, Kilpatrick BA, Huang YT, Pagano JS. Detection of human cytomegalovirus and analysis of strain variation. Yale J Biol Med 1976; 49: 29-43.
66. Pritchett RF. DNA nucleotide sequence heterogeneity between the Towne and AD169 strains of cytomegalovirus. J Virol 1980; 36: 152-161.
67. Chou SW. Reactivation and recombination of multiple cytomegalovirus strains from individual organ donors. J Infect Dis 1989; 160: 11-15.
68. Gibson W. Immediate-early proteins of human cytomegalovirus strains AD169, Davis, and Towne differ in electrophoretic mobility. Virology 1981; 112: 350-354.
69. Drew WL, Sweet ES, Miner RC, Mocarski ES. Multiple infections by cytomegalovirus in patients with acquired immunodeficiency syndrome: documentation by Southern blot hybridization. J Infect Dis 1984; 150: 952-953.
70. Chandler SH, McDougall JK. Comparison of restriction site polymorphisms among clinical isolates and laboratory strains of human cytomegalovirus. J Gen Virol 1986; 67: 2179-2192.
71. Chou SW. Differentiation of cytomegalovirus strains by restriction analysis of DNA sequences amplified from clinical specimens. J Infect Dis 1990; 162: 738-742.
72. Rasmussen L, Geissler A, Winters M. Inter- and intragenic variations complicate the molecular epidemiology of human cytomegalovirus. J Infect Dis 2003; 187: 809-819.
73. Britt WJ, Mach M. Human cytomegalovirus glycoproteins. Intervirology 1996; 39: 401-412.
74. Boppana SB, Rivera LB, Fowler KB, Mach M, Britt WJ. Intrauterine transmission of cytomegalovirus to infants of women with preconceptional immunity. N Engl J Med 2001; 344: 1366-1371.
75. Plotkin SA. Vaccination against cytomegalovirus. Arch Virol Suppl 2001; 17: 121-134.
76. Prichard MN, Penfold ME, Duke GM, Spaete RR, Kemble GW. A review of genetic differences between limited and extensively passaged human cytomegalovirus strains. Rev Med Virol 2001; 11: 191-200.
77. Pass RF, Duliege AM, Boppana S et al. A subunit cytomegalovirus vaccine based on recombinant envelope glycoprotein B and a new adjuvant. J Infect Dis 1999; 180: 970-975.
78. Mitchell DK, Holmes SJ, Burke RL, Duliege AM, Adler SP. Immunogenicity of a recombinant human cytomegalovirus gB vaccine in seronegative toddlers. Pediatr Infect Dis J 2002; 21: 133-138.
79. Adler SP, Hempfling SH, Starr SE, Plotkin SA, Riddell S. Safety and immunogenicity of the Towne strain cytomegalovirus vaccine. Pediatr Infect Dis J 1998; 17: 200-206.
80. Gonczol E, Plotkin S. Development of a cytomegalovirus vaccine: Lessons from recent clinical trials. Expert Opin Biol Ther 2001; 1: 401-412.
81. Adler SP, Starr SE, Plotkin SA et al. Immunity induced by primary human cytomegalovirus infection protects against secondary infection among women of childbearing age. J Infect Dis 1995; 171: 26-32.
82. Chou SW, Dennison KM. Analysis of interstrain variation in cytomegalovirus glycoprotein B sequences encoding neutralization-related epitopes. J Infect Dis 1991; 163: 1229-1234.
83. Compton T, Nowlin DM, Cooper NR. Initiation of human cytomegalovirus infection requires initial interaction with cell surface heparan sulfate. Virology 1993; 193: 834-841.
84. Chern KC, Chandler DB, Martin DF, Kuppermann BD, Wolitz RA, Margolis TP. Glycoprotein B subtyping of cytomegalovirus (CMV) in the vitreous of patients with AIDS and CMV retinitis. J Infect Dis 1998; 178: 1149-1153.
85. Tarrago D, Quereda C, Tenorio A. Different cytomegalovirus glycoprotein B genotype distribution in serum and cerebrospinal fluid specimens determined by a novel multiplex nested PCR. J Clin Microbiol 2003; 41: 2872-2877.
86. Utz U, Britt W, Vugler L, Mach M. Identification of a neutralizing epitope on glycoprotein gp58 of human cytomegalovirus. J Virol 1989; 63: 1995-2001.
87. Zipeto D, Hong C, Gerna G et al. Geographic and demographic differences in the frequency of human cytomegalovirus gB genotypes 1-4 in immunocompromised patients. AIDS Res Hum Retroviruses 1998; 14: 533-536.
88. Numazaki K, Ikehata M, Chiba S. Subtyping of cytomegalovirus strains obtained from immunocompetent children. In Vivo 2000; 14: 745-746.
89. Schoppel K, Kropff B, Schmidt C, Vornhagen R, Mach M. The humoral immune response against human cytomegalovirus is characterized by a delayed synthesis of glycoprotein-specific antibodies. J Infect Dis 1997; 175: 533-544.
90. Humar A, Kumar D, Gilbert C, Boivin G. Cytomegalovirus (CMV) glycoprotein B genotypes and response to antiviral therapy, in solid-organ-transplant recipients with CMV disease. J Infect Dis 2003; 188: 581-584.
91. Coaquette A, Bourgeois A, Dirand C, Varin A, Chen W, Herbein G. Mixed cytomegalovirus glycoprotein B genotypes in immunocompromised patients. Clin Infect Dis 2004; 39: 155-161.
92. Lang DJ, Kovacs AA, Zaia JA et al. Seroepidemiologic studies of cytomegalovirus and Epstein-Barr virus infections in relation to human immunodeficiency virus type 1 infection in selected recipient populations. Transfusion Safety Study Group. J AIDS 1989; 2: 540-549.
93. Bongarts A, von Laer D, Vogelberg C et al. Glycoprotein B genotype of human cytomegalovirus: Distribution in HIV-infected patients. Scand J Infect Dis 1996; 28: 447-449.
94. Spector SA, Hirata KK, Newman TR. Identification of multiple cytomegalovirus strains in homosexual men with acquired immunodeficiency syndrome. J Infect Dis 1984; 150: 953-956.
95. Steininger C, Schmied B, Sarcletti M, Geit M, Puchhammer-Stockl E. Cytomegalovirus genotypes present in cerebrospinal fluid of HIV-infected patients. AIDS 2005; 19: 273-278.
96. Haberland M, Meyer-Konig U, Hufert FT. Variation within the glycoprotein B gene of human cytomegalovirus is due to homologous recombination. J Gen Virol 1999; 80: 1495-1500.
97. Garrido RS, Aguado JM, Diaz-Pedroche C et al. A review of critical periods for opportunistic infection in the new transplantation era. Transplantation 2006; 82: 1457-1462.
98. Akalin E, Sehgal V, Ames S et al. Cytomegalovirus disease in high-risk transplant recipients despite ganciclovir or valganciclovir prophylaxis. Am J Transplant 2003; 3: 731-735.
99. Boeckh M, Leisenring W, Riddell SR et al. Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: Importance of viral load and T-cell immunity. Blood 2003; 101: 407-414.
100. Slifkin M, Tempesti P, Poutsiaka DD, Snydman DR. Late and atypical cytomegalovirus disease in solid-organ transplant recipients. Clin Infect Dis 2001; 33: E62-E68.
101. Shibolet O, Ilan Y, Kalish Y et al. Late cytomegalovirus infection occurring two or more years following liver transplantation: A report of seven cases and review of the literature. Transplant Proc 2003; 35: 663-664.
102. Li CR, Greenberg PD, Gilbert MJ, Goodrich JM, Riddell SR. Recovery of HLA-restricted cytomegalovirus (CMV)-specific T-cell responses after allogeneic bone marrow transplant: Correlation with CMV disease and effect of ganciclovir prophylaxis. Blood 1994; 83: 1971-1979.
103. Wade JC, Day LM, Crowley JJ, Meyers JD. Recurrent infection with herpes simplex virus after marrow transplantation: Role of the specific immune response and acyclovir treatment. J Infect Dis 1984; 149: 750-756.
104. Kletzmayr J, Kreuzwieser E, Watkins-Riedel T, Berlakovich G, Kovarik J, Klauser R. Long-term oral ganciclovir prophylaxis for prevention of cytomegalovirus infection and disease in cytomegalovirus high-risk renal transplant recipients. Transplantation 2000; 70: 1174-1180.
105. Steininger C, Kundi M, Kletzmayr J, Aberle SW, Popow-Kraupp T. Antibody maturation and viremia after primary cytomegalovirus infection, in immunocompetent patients and kidney-transplant patients. J Infect Dis 2004; 190: 1908-1912.
106. Singh N. Late-onset cytomegalovirus disease as a significant complication in solid organ transplant recipients receiving antiviral prophylaxis: A call to heed the mounting evidence. Clin Infect Dis 2005; 40: 704-708.
107. Snydman DR. The case for cytomegalovirus prophylaxis in solid organ transplantation. Rev Med Virol 2006; 16: 289-295.
108. Singh N, Yu VL, Mieles L, Wagener MM, Miner RC, Gayowski T. High-dose acyclovir compared with short-course preemptive ganciclovir therapy to prevent cytomegalovirus disease in liver transplant recipients. A randomized trial. Ann Intern Med 1994; 120: 375-381.
109. Brennan DC, Garlock KA, Singer GG et al. Prophylactic oral ganciclovir compared with deferred therapy for control of cytomegalovirus in renal transplant recipients. Transplantation 1997; 64: 1843-1846.
110. Hughes RA, Rees JH. Clinical and epidemiologic features of Guillain-Barre syndrome. J Infect Dis 1997; 176 (suppl 2): S92-S98.
111. Giovannoni G, Hartung HP. The immunopathogenesis of multiple sclerosis and Guillain-Barre syndrome. Curr Opin Neurol 1996; 9: 165-177.
112. Hughes RA, Hadden RD, Gregson NA, Smith KJ. Pathogenesis of Guillain-Barre syndrome. J Neuroimmunol 1999; 100: 74-97.
113. Yuki N. Infectious origins of, and molecular mimicry in, Guillain-Barre and Fisher syndromes. Lancet Infect Dis 2001; 1: 29-37.
114. Dowling PC, Cook SD. Role of infection in Guillain-Barrésyndrome: laboratory confirmation of herpesviruses in 41 cases. Ann Neurol 1981; 9 (suppl): 44-55.
115. Jacobs BC, Rothbarth PH, van der MechéFG et al. The spectrum of antecedent infections in Guillain-Barrésyndrome: A case-control study. Neurology 1998; 51: 1110-1115.
116. Winer JB, Hughes RA, Anderson MJ, Jones DM, Kangro H, Watkins RP. A prospective study of acute idiopathic neuropathy. II. Antecedent events. J Neurol Neurosurg Psychiatry 1988; 51: 613-618.
117. Steininger C, Popow-Kraupp T, Seiser A, Gueler N, Stanek G, Puchhammer E. Presence of cytomegalovirus in cerebrospinal fluid of patients with Guillain-Barre syndrome. J Infect Dis 2004; 189: 984-989.
118. Visser LH, van der Méche FG, Meulstee J et al. Cytomegalovirus infection and Guillain-Barre syndrome: The clinical, electrophysiologic, and prognostic features. Dutch Guillain-Barre Study Group. Neurology 1996; 47: 668-673.
119. Steininger C, Seiser A, Gueler N et al. Primary cytomegalovirus infection in patients with Guillain-Barre syndrome. J Neuroimmunol 2007; 183: 214-219.
120. Zanghellini F, Boppana SB, Emery VC, Griffiths PD, Pass RF. Asymptomatic primary cytomegalovirus infection: Virologic and immunologic features. J Infect Dis 1999; 180: 702-707.